|
|
|
|
|
Board of Directors
William D. Young has served as Chief Executive Officer since November 1999 and has served as Chairman of the Board since May 1999. From March 1997 to October 1999, Mr. Young was Chief Operating Officer at Genentech, Inc., a biotechnology company. As COO at Genentech, Mr. Young was responsible for all of the company's development, operations and commercial functions. Mr. Young joined Genentech in 1980 as Director of Manufacturing and Process Sciences and held various executive positions prior to becoming COO. Prior to joining Genentech, Mr. Young was employed by Eli Lilly and Company for 14 years. Mr. Young is a member of the board of directors of Biogen IDEC, Inc., Human Genome Sciences, Inc. and Theravance, Inc. He received his bachelor's degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University.
William Jenkins, MD has served as a director since September 2000. Dr. Jenkins has been a consultant and advisor to pharmaceutical companies and investment and venture capital firms in the health sector since 1999. From 1997 to 1999, he served as Head of Clinical Development and Regulatory Affairs for Ciba-Geigy, and later for post-merger Novartis Pharma AG. Prior to that, Dr. Jenkins was Head of Worldwide Clinical Research at Glaxo and a Deputy Head in the UK Drug Regulatory Agency. Dr. Jenkins is a member of the board of directors of Tanox, Inc., BTG plc, Glycart AG, Esbatech AG and Eurand Pharmaceutical Holdings BV. Dr. Jenkins received his MD from Cambridge University and has a specialist accreditation in internal medicine and gastroenterology.
Edmon R. Jennings has served as a director since May 2001. Since July 2003, Mr. Jennings has served as President and CEO of Angiogenix, Inc., a biopharmaceutical company. From February 2000 to June 2003, Mr. Jennings was Chief Commercialization Officer at Pain Therapeutics, Inc., a medical research and development company. From 1985 to 2000, Mr. Jennings held senior management positions at Genentech, Inc., including Vice President of Corporate Development, Vice President of Sales and Marketing and Vice President of Sales. Prior to Genentech, Mr. Jennings held positions for 12 years with Bristol-Myers Oncology and Bristol Laboratories, both of which were divisions of Bristol-Myers (now Bristol-Myers Squibb), a pharmaceutical company. Mr. Jennings received his BA in liberal arts from the University of Michigan at Ann Arbor.
Cristina H. Kepner has served as a director since May 1996. Ms. Kepner is Advisor at Invemed Associates LLC, an investment banking firm. From 1978 to December 2000, Ms. Kepner was a Director, Executive Vice President and Corporate Finance Director at Invemed Associates LLC. Ms. Kepner serves on the board of directors of Quipp, Inc. and Cepheid. She received her BA from Pace University.
John D. Mendlein, PhD, JD has served as a director since December 2004. Dr. Mendlein was a member of ACLARA Biosciences, Inc.'s board of directors from April 2003 to December 2004. Dr. Mendlein is Chief Executive Officer of Compound Therapeutics. Dr. Mendlein is Chairman of Affinium Pharmaceuticals, Inc., a drug discovery company, and also served as Chief Executive Officer from November 2000 to June 2005. Prior to joining Affinium, Dr. Mendlein served as Chief Knowledge Officer, General Counsel and Senior Vice President, Intellectual Property of Aurora Biosciences Corporation, from 1996 until 2000. Dr. Mendlein holds a PhD in physiology and biophysics from the University of California, Los Angeles and a JD degree from the University of California, Hastings College of Law.
David H. Persing, MD, PhD has served as a director since December 2000. Dr. Persing received his BA degree in biochemistry from San Jose State University, and his MD and PhD (biochemistry and biophysics) concurrently from the University of California, San Francisco. After completing his residency in clinical pathology and fellowship training at Yale University in 1989, Dr. Persing was appointed to the medical and research staff of the Mayo Clinic, where he became Director of the Molecular Microbiology Laboratory and an Associate Professor at the Mayo Medical School. In August 1999, Dr. Persing became employed at Corixa Corporation, a research and development-based biotechnology company, where he is Vice President of Discovery Research, as well as a Principal Investigator in the Infectious Disease Research Institute, a non-profit research organization. Dr. Persing serves on the board of directors of Cepheid.
Christine A. White, MD has served as a director since August 2008. Dr. White received her medical degree from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology, completing her postdoctoral work with the Molecular Biology Breast Cancer/Dulbecco Laboratory of the Salk Institute. Dr. White held a number of executive positions at Biogen Idec from 1996 to 2005 and most recently served as Senior Vice President of Global Medical Affairs. While at Biogen Idec, she played a key role in the clinical development and commercialization of both Rituxan® and Zevalin®. Starting in 1984 Dr. White was Medical Director of Oncology Research and Chair of the Department of Medicine at Scripps Memorial Hospitals. In 1994 she became Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center. Dr. White is a past Chair of the California Breast Cancer Research Program’s Advisory Council and currently serves on the editorial boards of several peer reviewed scientific publications. Dr. White also serves on the board of directors of Pharmacyclics, Inc., Arena Pharmaceuticals, and Apoptos, Inc.
|
|
 |
|
